We expect overall revenue growth to remain low, due to the continued impact of the decline in legacy drug sales. As always, the three main oncology drugs will continue to support the topline, although there could be an uptick in Tamiflu’s sales. Some of the recently launched drugs such as Perjeta and Kadcyla are likely to contribute greatly to incremental revenues.

Topics:  tamiflu s   perjeta   kadcyla   roche   oncology drugs   revenue growth   sales   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News